Business Context and Reporting Period
This Form 8-K, dated February 5, 2013, is filed by Duke Energy Corporation and its subsidiary Florida Power Corporation d/b/a Progress Energy Florida, Inc. (PEF). The report addresses the strategic decision to retire the Crystal River 3 (CR3) nuclear power plant and the resolution of related insurance claims.
Key Financial Metrics
- Impairment Charge: PEF will record approximately $195 million in impairments in the fourth quarter of 2012 related to CR3 plant balances allocated to wholesale customers.
- Insurance Proceeds: PEF reached a resolution with Nuclear Electric Insurance Limited (NEIL) for a total of $835 million in insurance proceeds ($305 million previously paid plus $530 million additional).
- Accounting Treatment: The impairment will be recorded as an increase to goodwill in purchase accounting related to the Duke Energy acquisition of Progress Energy, Inc.
Material Changes and Regulatory Context
PEF announced its intention to retire the CR3 nuclear plant. Under a 2012 settlement approved by the Florida Public Service Commission (FPSC), PEF intends to recover retail investment in CR3, including accrued carrying charges, over a 20-year period beginning no earlier than 2017. The FPSC is expected to review the retirement decision later in 2013 as part of "Phase 2" of the CR3 delamination regulatory docket.
Outlook, Risks, and Management Commentary
Management has resolved insurance coverage claims through mediation, with the additional $530 million payment contingent on the mediator's proposal accepted by both parties. PEF will request the FPSC to review this resolution in the currently stayed "Phase 3" of the regulatory docket. The filing explicitly states that the outcome of the next phases of the CR3 regulatory docket pending before the FPSC cannot be predicted.
Investor Verification Checklist
- Verify the timing and conditions for the 20-year recovery of CR3 retail investment starting in 2017.
- Confirm the FPSC's approval of the $835 million insurance proceeds in Phase 3 of the regulatory docket.
- Review the impact of the $195 million impairment on the consolidated financial statements and goodwill valuation.
- Monitor the status of the "Phase 2" regulatory review regarding the CR3 retirement decision.